Richards, Merrill & Peterson, Inc. Gilead Sciences, Inc. Transaction History
Richards, Merrill & Peterson, Inc.
- $191 Billion
- Q4 2024
A detailed history of Richards, Merrill & Peterson, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Richards, Merrill & Peterson, Inc. holds 110 shares of GILD stock, worth $11,577. This represents 0.01% of its overall portfolio holdings.
Number of Shares
110Holding current value
$11,577% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding GILD
# of Institutions
2,083Shares Held
1.02BCall Options Held
8.73MPut Options Held
9.63M-
Black Rock Inc. New York, NY121MShares$12.7 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA116MShares$12.2 Billion0.19% of portfolio
-
Capital World Investors Los Angeles, CA71.7MShares$7.55 Billion1.05% of portfolio
-
State Street Corp Boston, MA60.4MShares$6.36 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA57.9MShares$6.1 Billion1.15% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $132B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...